Research programme: rheumatoid arthritis therapeutics - BioPatterns
Latest Information Update: 04 Aug 2016
At a glance
- Originator BioPatterns
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 04 Aug 2016 Preclinical trials in Rheumatoid arthritis in Czech Republic (unspecified route)
- 04 Aug 2016 Research programme: rheumatoid arthritis therapeutics - BioPatterns is available for licensing as of 04 Aug 2016. http://www.biopatterns.cz/